Thanks, Matt, and hello, everyone. Before I cover the portfolio and our outlook on the market, I wanted to add my thoughts on the changes Matt outlined. Our private credit platform is a core focus for Oaktree, and OCSL is a critical part of our franchise. While we acknowledge the challenged performance over recent quarters, we remain committed to OCSL. We believe the equity purchase by Oaktree at a significant premium to the market price is a clear signal of our support. I firmly believe that the actions we laid out today demonstrate our commitment to position OCSL for further growth and success. With that said, I’ll begin with an overview of our portfolio activity in the quarter before addressing our view on current market conditions. Our portfolio remains well diversified with $2.8 billion of fair value invested across 136 companies as of December 31, 2024, and the weighted average yield on our debt investments remains healthy at 10.7%. During the first quarter, we invested $198 million in five new and eight existing portfolio companies, in line with our strategy to invest at the top of the capital structure. 82% of our portfolio is now in first lien positions, up from 78% a year ago. We remain focused on investing in larger companies and strong sectors that further diversify our portfolio. In the first quarter, the median EBITDA of our portfolio companies was $142 million, and the median leverage was 5.4x. The leverage ratios for our portfolio companies increased slightly from the previous quarter, but remain below the average for middle market companies. The vast majority of our portfolio companies are performing well in the current environment with a weighted average interest coverage ratio of 2.1x, assuming current base rates. I’ll now address the credit quality of the portfolio. In the first quarter, one investment was restructured and removed from non-accrual status. However, we classified one new investment as non-accrual and took further write-downs on other investments. As a result, the investments on non-accrual status at quarter end were 3.9% of the portfolio at fair value and 5.1% at cost, relatively unchanged from the prior quarter. The new addition to the non-accrual list this quarter is Dominion Diagnostics, a clinical toxicology testing company in which we hold a first lien term loan and a revolver. Although the company continued to pay cash interest in the December quarter, it has struggled to grow EBITDA and faces liquidity challenges looking ahead, so we felt it was prudent to place it on non-accrual. We are working closely with management to address these matters. Although not new to our non-accrual list, we placed the first lien term loans for Dialyze on non-accrual. As a reminder, Dialyze provides hemodialysis services directly to patients in skilled nursing facilities. Our original investment in Dialyze included a first lien term loan and warrants. In connection with amendment activity and funding incremental amounts on the term loan, we received a relatively, small mezzanine loan at zero cash cost. We put this smaller mezzanine loan on non-accrual last summer as the company’s plans to achieve profitability was taking longer than originally forecasted. Unfortunately, the situation has not materially improved and given the ongoing cash needs of the company, we place the first lien term loans on non-accrual. We are in ongoing discussions with the company and are evaluating all options. Along with the investments on non-accrual we further wrote down several underperforming assets. These write downs are concentrated in a handful of struggling investments. We continue to monitor these names closely while taking a conservative approach to their valuation. Next, I want to highlight some of the positive developments in the portfolio. I will begin with a discussion on Finthrive, which was removed from the non-accrual list. Finthrive is a software company that helps healthcare clients manage their revenue and cash flow and was successfully restructured in November of last year. As part of the transaction, the company raised new capital, extended the maturity of its revolving credit facilities, and delevered its balance sheet. In addition, we continue to make progress with several other names on non-accrual. For example, EBITDA trends have remained positive for all web leads and Avery successfully closed additional condo sales in 2024, including a penthouse unit. We are optimistic these positive trends in these portfolio companies will continue into the New Year. Turning to our view of the market environment, although the Fed lowered rates by 50 basis points in the last quarter of 2024 and may reduce rates further in 2025, elevated interest rates remain a challenge for many borrowers, especially those with levered balance sheets. Even with inflation beginning to subside, we do not believe interest rates are going back to ultra-low levels. During the fiscal first quarter spreads continue to tighten compared to the fourth quarter. Competition between broadly syndicated loans and private credit drove spreads lower which now seem to be stabilizing as many companies have already repriced or refinanced their debt. We believe a more favorable regulatory environment and an expected increase in private equity activity will increase opportunities for M&A and IPOs over the years ahead. This increased deal flow should help fix the supply and demand imbalance, we have seen between lenders and borrowers in the private credit space, easing the competitive pressure that has contributed to spread compression in recent years. The uptick in dealmaking is also likely to create a strong pipeline in 2025. At the same time, private equity firms are sitting on over $2 trillion of dry powder. Conditions for deal volume are recovering with declining rates along with valuation gaps between buyers and sellers improving. We believe all of these factors combined suggest a positive outlook for the sector in 2025. I’ll now turn the call over to Raghav to share details on our originations for the quarter.